Atlas Trials

A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Clinical trial NCT07557004 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT07557004
Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
HR+ / HER2- Advanced Breast Cancer
Start date
2025-09-30
Primary completion
2027-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.